First-line hepatic infusion of pirarubicin in patients with isolated liver metastases: is it really promising?
Fakih
M
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000473:pathology*; D004317:Doxorubicin / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D005472:Fluorouracil / Q000008:administration & dosage; D017048:Health Care Costs; D006499:Hepatic Artery; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D007261:Infusions, Intra-Arterial; D000077146:Irinotecan; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D018579:Patient Selection; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D000077146:Irinotecan; D004317:Doxorubicin; C027260:pirarubicin; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin